JP4451599B2 - 細胞増殖疾患の予防及び／又は治療薬の調製におけるピラゾリン誘導体の使用 - Google Patents

細胞増殖疾患の予防及び／又は治療薬の調製におけるピラゾリン誘導体の使用 Download PDF

Info

Publication number
JP4451599B2
JP4451599B2 JP2002578948A JP2002578948A JP4451599B2 JP 4451599 B2 JP4451599 B2 JP 4451599B2 JP 2002578948 A JP2002578948 A JP 2002578948A JP 2002578948 A JP2002578948 A JP 2002578948A JP 4451599 B2 JP4451599 B2 JP 4451599B2
Authority
JP
Japan
Prior art keywords
trifluoromethyl
group
pyrazole
dihydro
methylsulfonylphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002578948A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004525166A5 (https=
JP2004525166A (ja
Inventor
アルティセント マリア ロサ クベレス
ロメロ フアナ マリア ベロッカル
ロベット マリア モンセラット コンチホー
コンスタンサ ジョルディ フリゴラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Esteve Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Pharmaceuticals SA filed Critical Esteve Pharmaceuticals SA
Publication of JP2004525166A publication Critical patent/JP2004525166A/ja
Publication of JP2004525166A5 publication Critical patent/JP2004525166A5/ja
Application granted granted Critical
Publication of JP4451599B2 publication Critical patent/JP4451599B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2002578948A 2001-04-06 2002-03-21 細胞増殖疾患の予防及び／又は治療薬の調製におけるピラゾリン誘導体の使用 Expired - Fee Related JP4451599B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200100818A ES2174757B1 (es) 2001-04-06 2001-04-06 Empleo de derivados de firazolinas en la elaboracion de un medicamentopara la prevencion y/o el tratamiento de enfermedades proliferativas celulares.
PCT/ES2002/000137 WO2002080909A1 (es) 2001-04-06 2002-03-21 Empleo de derivados de pirazolinas en la elaboración de un medicamento para la prevención y/o el tratamiento de enfermedades proliferativas celulares

Publications (3)

Publication Number Publication Date
JP2004525166A JP2004525166A (ja) 2004-08-19
JP2004525166A5 JP2004525166A5 (https=) 2005-09-15
JP4451599B2 true JP4451599B2 (ja) 2010-04-14

Family

ID=8497370

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002578948A Expired - Fee Related JP4451599B2 (ja) 2001-04-06 2002-03-21 細胞増殖疾患の予防及び／又は治療薬の調製におけるピラゾリン誘導体の使用

Country Status (26)

Country Link
US (1) US20040034082A1 (https=)
EP (2) EP1516621A3 (https=)
JP (1) JP4451599B2 (https=)
KR (1) KR20040025912A (https=)
CN (2) CN1299682C (https=)
AT (1) ATE326966T1 (https=)
AU (1) AU2002246152B2 (https=)
BR (1) BR0208805A (https=)
CA (1) CA2442974C (https=)
CY (1) CY1105523T1 (https=)
DE (1) DE60211681T2 (https=)
DK (1) DK1384477T3 (https=)
ES (2) ES2174757B1 (https=)
HU (1) HUP0400918A3 (https=)
IL (1) IL158269A0 (https=)
IS (1) IS6973A (https=)
MA (1) MA27019A1 (https=)
MX (1) MXPA03009124A (https=)
NO (1) NO20034470L (https=)
NZ (1) NZ529304A (https=)
PL (1) PL365220A1 (https=)
PT (1) PT1384477E (https=)
RU (1) RU2305545C2 (https=)
UA (1) UA75402C2 (https=)
WO (1) WO2002080909A1 (https=)
ZA (1) ZA200308626B (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077910A1 (en) * 2004-02-16 2005-08-25 Laboratorios Del Dr. Esteve S.A. Pyrazoline derivatives useful for the treatment of cancer
ES2238923B1 (es) * 2004-02-16 2006-11-01 Laboratorios Del Dr. Esteve, S.A. Nuevos derivados pirazolinicos sustituidos.
US7998996B2 (en) 2004-02-17 2011-08-16 Laboratorios Del Dr. Esteve S.A. Substituted pyrazoline compounds for reducing triglycerides in blood
EP1637522A1 (en) * 2004-09-16 2006-03-22 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds for reducing triglycerides in blood
CA2556568A1 (en) * 2004-02-17 2005-08-25 Laboratorios Del Dr. Esteve S.A. Substituted pyrazoline compounds for reducing triglycerides in blood
TW200533657A (en) 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
EP1749525A1 (en) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Combination of substituted pyrazolines and anti-addictive agent
WO2007009703A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. New formulations of substituted pyrazoline compounds
EP1746090A1 (en) * 2005-07-15 2007-01-24 Laboratorios del Dr. Esteve S.A. Sustituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood
EP1849776A1 (en) * 2006-04-26 2007-10-31 Laboratorios Del Dr. Esteve, S.A. Azepane- or Azocane-substituted pyrazoline compounds, their preparation and use as medicaments
ES2327379B1 (es) * 2005-07-15 2010-05-28 Laboratorios Del Dr. Esteve, S.A. Compuestos de pirazolina indolinsustituidos, su preparacion y su uso como medicamentos.
ES2319074B1 (es) * 2005-07-15 2009-12-03 Laboratorios Del Dr. Esteve, S.A. Combinacion de principios activos.
ES2327203B1 (es) * 2005-07-15 2010-06-07 Laboratorios Del Dr. Esteve, S.A. Uso de compuestos de pirazolina sustituidos para el tratamiento de trastornos relacionados con la coagulacion.
US7897589B2 (en) 2005-07-15 2011-03-01 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
EP1743892A1 (en) * 2005-07-15 2007-01-17 Laboratorios del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
EP1743642A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazoline compounds and their derivatives for the treatment of cannabinoid system-associated diseases
ES2336883B1 (es) * 2005-07-15 2011-03-22 Laboratorios Del Dr. Esteve, S.A. Compuestos de pirazolina sustituidos, con una estereoquimica predeterminada, para la reduccion de trigliceridos en sangre.
ES2326725B1 (es) * 2005-07-15 2010-05-11 Laboratorios Del Dr. Esteve, S.A. Uso de compuestos de pirazolina sustituidos para el tratamiento de trastornos alimentarios, que incluyen la obesidad o el sindrome metabolico en pacientes con diabetes desarrollada.
EP1743639A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazoline compounds for the treatment of coagulation related diseases
EP1749526A1 (en) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes
WO2007009706A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood
EP1749527A1 (en) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazoline compounds for the treatment of the lipid parameters of the metabolic syndrome
EP1743889A1 (en) * 2005-07-15 2007-01-17 Laboratorios del Dr. Esteve S.A. Sustituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood
EP1849784A1 (en) * 2006-04-26 2007-10-31 Laboratorios Del Dr. Esteve, S.A. Indoline-substituted pyrazoline compounds, their preparation and use as medicaments
EP1743637A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome
ES2316306B1 (es) * 2005-07-15 2009-11-23 Laboratorios Del Dr. Esteve, S.A. Combinacion de un compuesto de pirazolina sustituido y un farmaco utilizado en trastornos relacionados con los alimentos.
ES2326857B1 (es) * 2005-07-15 2010-05-11 Laboratorios Del Dr. Esteve, S.A. Uso de compuestos de pirazolina sustituidos para el tratamiento de los parametros lipidicos del sindrome metabolico.
EP1743636A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Combination of a substituted pyrazoline compound and a drug used in food-related disorders
WO2007009699A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A Use of substituted pyrazoline compounds and their derivatives for the treatment of cannabinoid system-associated diseases
WO2007009701A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome
EP1743890A1 (en) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. 4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments
EP1743643A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. New formulations of substituted pyrazoline compounds
KR101457637B1 (ko) * 2012-10-24 2014-11-20 건국대학교 산학협력단 디히드로피라졸카르보티오아미드 유도체 및 그 제법 및 그 유도체를 포함하는 항암제 조성물
CN103664785A (zh) * 2013-11-04 2014-03-26 南京大学 一类新颖的二氢吡唑磺胺衍生物的合成及在抗癌药物中的应用
WO2023043778A1 (en) * 2021-09-14 2023-03-23 Maverick Gold (Nv), Llc Methods and systems for titling and trading alternative reserves

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0674624T3 (da) * 1992-12-17 1999-09-13 Pfizer Pyrazoler med CRF-antagonistisk aktivitet
ES2141916T3 (es) * 1993-11-30 2000-04-01 Searle & Co Pirazolil-bencenosulfonamidas sustituidas para el tratamiento de la inflamacion.
US5604253A (en) * 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
ES2137138B1 (es) * 1998-05-29 2000-09-16 Esteve Labor Dr Derivados de pirazolinas, su preparacion y su aplicacion como medicamentos.
US6376519B1 (en) * 1999-06-16 2002-04-23 Temple University-Of The Commonwealth Of Higher Education 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines and inhibitors of cyclooxygenase-2

Also Published As

Publication number Publication date
EP1516621A2 (en) 2005-03-23
CY1105523T1 (el) 2010-07-28
HK1067311A1 (en) 2005-04-08
IL158269A0 (en) 2004-05-12
NZ529304A (en) 2006-02-24
CA2442974A1 (en) 2002-10-17
EP1384477B1 (en) 2006-05-24
EP1516621A3 (en) 2005-05-04
BR0208805A (pt) 2004-07-13
CN1509171A (zh) 2004-06-30
CN1299682C (zh) 2007-02-14
AU2002246152B2 (en) 2007-05-31
ES2264723T3 (es) 2007-01-16
ES2174757A1 (es) 2002-11-01
MXPA03009124A (es) 2005-04-11
RU2003132457A (ru) 2005-04-10
DE60211681T2 (de) 2007-05-16
HUP0400918A3 (en) 2004-10-28
JP2004525166A (ja) 2004-08-19
EP1384477A1 (en) 2004-01-28
IS6973A (is) 2003-10-03
DE60211681D1 (de) 2006-06-29
US20040034082A1 (en) 2004-02-19
MA27019A1 (fr) 2004-12-20
WO2002080909A1 (es) 2002-10-17
PT1384477E (pt) 2006-09-29
NO20034470D0 (no) 2003-10-06
HUP0400918A2 (hu) 2004-07-28
ATE326966T1 (de) 2006-06-15
CA2442974C (en) 2010-02-23
UA75402C2 (en) 2006-04-17
KR20040025912A (ko) 2004-03-26
NO20034470L (no) 2003-12-05
PL365220A1 (en) 2004-12-27
ZA200308626B (en) 2004-11-05
CN1698602A (zh) 2005-11-23
ES2174757B1 (es) 2003-11-01
RU2305545C2 (ru) 2007-09-10
DK1384477T3 (da) 2006-08-21

Similar Documents

Publication Publication Date Title
JP4451599B2 (ja) 細胞増殖疾患の予防及び／又は治療薬の調製におけるピラゾリン誘導体の使用
USRE38963E1 (en) Pyrazoline derivatives, their preparation and application as medicaments
JP5583968B2 (ja) オキソ置換イミダゾ［１，２ｂ］ピリダジン、その調製方法、及び医薬としての使用
KR102598246B1 (ko) Jak 저해제로서 헤테로사이클릭 화합물, 및 이의 염 및 치료학적 용도
JP2005510472A (ja) ３−置換−４−ピリミドン誘導体
JP5680640B2 (ja) ピラゾール誘導体、これらの調製およびこれらの治療用途
TWI690515B (zh) 二氫嘧啶-２-酮化合物及其醫藥用途
CN117088876A (zh) 一种高活性Wnt通路抑制剂化合物
CN106459050A (zh) 三环化合物以及jak抑制剂
ES2861317T3 (es) Moduladores de SOCE, composiciones y usos de los mismos
US20210292315A1 (en) Selenium-containing isoxazolamine compound, preparation method therefor, and use thereof
HK1085671A (en) Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases
HK1067311B (en) Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases
JPH07165724A (ja) ピラゾール誘導体及び血液凝固阻害剤
AU2005212833A1 (en) Pyrazoline derivatives useful for the treatment of cancer

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090204

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090430

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090915

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20091102

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100105

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100128

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130205

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees